key: cord-0790994-ry7lcqt0
authors: Xie, Hongsheng; Yang, Xiufang; Cao, Yuan; Long, Xipeng; Shang, Huifang; Jia, Zhiyun
title: Role of lipoic acid in multiple sclerosis
date: 2021-12-28
journal: CNS Neurosci Ther
DOI: 10.1111/cns.13793
sha: 66e28f3095a2f559e571049654519fb755b2855a
doc_id: 790994
cord_uid: ry7lcqt0

Lipoic acid (LA) is an endogenous antioxidant that exists widely in nature. Supplementation with LA is a promising approach to improve the outcomes of patients with multiple sclerosis (MS). This systematic review aimed to provide a comprehensive overview of both in vitro and in vivo studies describing the pharmacokinetics, efficacy, safety, and mechanism of LA in MS‐related experiments and clinical trials. A total of 516 records were identified by searching five databases, including PubMed, Web of Science, Embase, Scopus, and Cochrane Library. Overall, we included 20 studies reporting LA effects in cell and mouse models of MS and 12 studies reporting LA effects in patients with MS. Briefly, cell experiments revealed that LA protected neurons by inhibiting the expression of inflammatory mediators and activities of immune cells. Experimental autoimmune encephalomyelitis mouse experiments demonstrated that LA consistently reduced the number of infiltrating immune cells in the central nervous system and decreased the clinical disability scores. Patients with MS showed relatively stable Expanded Disability Status Scale scores and better walking performance with few adverse events after the oral administration of LA. Notably, heterogeneity of this evidence existed among modeling methods, LA usage, MS stage, and trial duration. In conclusion, this review provides evidence for the anti‐inflammatory and antioxidative effects of LA in both in vitro and in vivo experiments; therefore, patients with MS may benefit from LA administration. Whether LA can be a routine supplementary therapy warrants further study.

Multiple sclerosis (MS) is a disabling autoimmune disease of the central nervous system (CNS) characterized by demyelination and neurodegeneration. 1 It affects approximately 2.5 million people worldwide and poses a growing burden to society. 2, 3 Relapsing-remitting MS (RRMS) is the most common initial course featuring alternate relapse and remission, and disability is aggravated gradually with illness development. 4 After approximately 20 years, around 90% of RRMS patients will develop secondary progressive MS (SPMS) characterized by progressive neurodegeneration without any definite remission periods. 5, 6 In addition to SPMS, progressive MS (PMS) also includes primary progressive MS featuring inapparent clinical relapses from the onset. At present, both immune and nonimmune mechanisms are believed to be involved in MS pathogenesis.

The "outside-in" hypothesis proposes that the inflammatory demyelinating process begins in the subarachnoid space and cortex and extends into the white matter. 7, 8 In this model, the invasion of peripheral immune cells disrupts the blood-brain barrier (BBB) integrity and contributes to the prolonged presence of inflammatory activity.

In RRMS, the interaction of monocytes and brain endothelial cells (ECs) produces massive reactive oxygen species (ROS), leading to the loss of tight junctions and migration of monocytes. 9 For T cells, the mutual recognition of lymphocyte function-associated antigen-1 (LFA-1), intercellular cell adhesion molecule-1 (ICAM-1), very late antigen-4 (VLA-4), and vascular cell adhesion molecule-1 (VCAM-1) permits them to cross the BBB. The release of matrix metalloprotein-9 (MMP-9) by T cells is also essential for the migration process.

Notably, infiltrated T cells can recruit macrophages, microglia, and astrocytes by secreting mediators, including tumor necrosis factorα (TNFα), interferonγ (IFNγ), and interleukins-17 (IL-17). 10, 11 These abnormally activated immune cells target neurons and the myelin sheath and drive MS relapse and progression. Therefore, several disease-modifying therapies (DMTs) can decrease relapse rates by immunomodulation. However, the potential risks of serious adverse events (AEs) and COVID-19 infection limit its clinical use to some extent. 12, 13 In PMS, inflammation is compartmentalized and mainly driven by the activities of innate microglia, astrocytes, and B cells. 11 Unfortunately, the efficacy of DMTs for PMS tends to be disappointing, motivating the search for a new treatment option. 14 Oxidative stress is another crucial driver of MS once the autoimmune system has caused damage to the CNS. 10 It occurs when an imbalance exists between excessive production of free radicals and insufficient biological ability to remove them. 15 The CNS is quite sensitive and vulnerable to oxidative stress because of its high oxygen consumption and lipid abundance. Oxidizing substances, such as ROS and nitrogen species, are usually produced by activated macrophage and microglial structures, causing damage to lipids, proteins, and DNA. Consequently, the CNS is variously disrupted through processes such as increased BBB permeability, myelin phagocytosis, and neurodegeneration. 16, 17 In the plasma of MS patients, the levels of antioxidants and total antioxidant capacity are decreased. 18, 19 Autopsy studies have also widely detected the damage induced by oxidative stress in cerebrospinal fluid and CNS tissues. 20, 21 Therefore, oxidative stress may be another hopeful therapeutic target of MS. At present, many antioxidant compounds have improved serological indicators in MS patients. 22 Vitamin D decreased the relapse rates as an antioxidant in RRMS patients. 23 However, the findings of the efficacy of antioxidants tend to be conflicting and confusing, strongly suggesting that the effect of using a single antioxidant is limited. Considering the above, an ideally effective medicine must possess the ability to prevent multiple pathogenic factors and outstanding BBB permeability.

Lipoic acid (LA), also known as thioctic acid, has become a hopeful complementary therapy in MS to target both inflammation and oxidative stress. LA is a double-sulfhydryl natural antioxidant with two enantiomers according to optical rotation: R-LA and S-LA.

Overall, R-LA exists widely in plants and animals, whereas S-LA is artificially synthesized to compose the racemic mixture (1:1 R/S-LA). 24 In the human body, R-LA is synthesized de novo by cysteine and fatty acids in small amounts; thus, it primarily depends on exogenous supplements such as organ meat, broccoli, and fruits. 25 For individuals, the racemic form can be absorbed rapidly after oral administration and participate in various biological metabolic pathways. First, it contributes to the synthesis of vitamin C and vitamin E. 26 Second, it is reduced to dihydro-LA (DHLA), and DHLA is involved in the biosynthesis of intracellular glutathione (GSH) and coenzyme Q10. 27, 28 Third, R-LA plays a crucial role in mitochondrial energy production as a cofactor for some enzymatic complexes in the Krebs cycle. 29 When other metabolic pathways are saturated, redundant LA (nearly 10%) will be excreted through the kidneys. 30 Over the past two decades, whether LA improves the quality of life of patients with MS has been intensively studied. 31 In mouse models of experimental autoimmune encephalomyelitis (EAE), LA increased the population of mature oligodendrocytes and alleviated neurological symptoms, suggesting that LA might protect and promote neuronal regeneration. 32, 33 However, the results of alleviated neurological symptoms were inconsistent for different administration pathways, timing, and dosage, making the evidence somewhat fragile. In patients with MS, LA reduced the Expanded Disability Status Scale (EDSS), although the between-group difference was not statistically significant. 34, 35 The confusing result regarding whether LA could improve patient outcomes probably resulted from the short trial duration. Additionally, the annualized percent brain volume change was less after 2 years of supplementation in the LA group, indicating that LA might prevent neuronal death and reduction. 36 More importantly, few AEs were reported when using LA as an oral preparation for 2 years. In summary, LA shows strong antioxidative and anti-inflammatory effects in MS, which makes it a potential candidate for complementary and long-term therapy.

To date, no study has systematically summarized the current findings of LA in MS, and some results appear to be controversial. A good review of both achievements and limitations will contribute to determining reliable evidence and research trends for future studies.

In this review, we aimed to provide comprehensive insight into the role of LA in MS, including the aspects of pharmacokinetics, efficacy, safety, and mechanism, in both in vitro and in vivo experiments. We hope that our work will contribute to the development of new drugs and combination therapy for patients with MS.

According to the guidelines of the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement, 37 English-language studies published from inception up to July 1, 2021, were collected by searching five databases: PubMed (Medline), EMBASE, Web of Science, Scopus, and Cochrane Library.

Identified search terms included ("multiple sclerosis" OR "MS") AND ("lipoic acid" OR "Thioctacid" OR "LA"). Additional records were identified manually through other sources, such as any related review papers and reference lists of all included studies to avoid missing relevant studies in the initial search. The whole search process was conducted by two authors independently (H.S.X. & X.F.Y.).

After removing duplicates, all the studies were screened for eligibility 

For the included studies, we collected the following information into a spreadsheet in Excel: (1) subject characteristics including age, sex, EDSS score, and MS duration; (2) MS-related model establishment in the preclinical experiments; (3) LA dosage (4) endpoints including efficacy, safety, pharmacokinetics, and mechanism; and (5) first author's name, publication date, study design, and follow-up duration.

For detailed data not shown in the full text, the e-mails were sent to the corresponding authors for help.

We obtained 516 potential records in the initial systematic search.

After the removal of duplicates, 143 studies were screened based on the title and abstract, leading to 59 full-text studies screened for eligibility. In this process, 27 articles were excluded because of irrelevant endpoints, nonoriginal studies, and combined antioxidant supplements. Finally, 32 intervention studies were included in this systematic review to investigate the effects of LA on efficacy, safety, pharmacokinetics, and mechanism. An overview of the study selection is presented in Figure 1 .

A rat experiment found that the duodenum was the best portion of the intestine for LA absorption and that R-LA showed a higher absorption percentage than S-LA. 40 Notably, two vital pathways are involved in the process of LA crossing the intestinal barrier: Na+/multivitamin F I G U R E 1 Preferred Reporting Items for Systematic Reviews flowchart (SMVT) and monocarboxylic acid (MCT) transporters. 41, 42 Under equilibrium conditions, human SMVT can simultaneously bind and transport two LA molecules into the mesenteric vein, and human MCT transports LA in an energy-and low-pH-dependent manner. In the patients with RRMS/SPMS and healthy volunteers, the pharmacokinetic parameters showed no significant difference, suggesting that the MS status did not influence LA metabolism. 43 In 54 patients with SPMS, pharmacokinetics showed no significant difference between the baseline and 1 year later, suggesting that the oral administration of LA was stable for long-term use. 44 In patients with MS, three studies found that the time to reach the peak concentration of R-LA was much shorter than that of the racemic form, indicating the quicker absorption of the R-configuration. 33 Notably, human SMVT and MCT are also expressed in brain microvessels and contribute to the transportation of LA across the BBB. 46, 47 In an in vitro experiment, LA showed the ability to cross the BBB and exert beneficial effects on the viability of astrocytes. 48 Besides, a rat experiment found that 14 C-labeled LA reached peak levels in the cortex, spinal cord, and sciatic nerve after one-half hour of oral administration, indicating that LA was taken up by both the CNS and peripheral nerves. 49 LA was also measured in the rat brain cortex, cerebellum, striatum, and hippocampus after intravenous and intraperitoneal administration. 50, 51 Notably, a recent rat experiment found that the LA did not cross the BBB as easily as supposed after the correction for blood volume, which emphasized that the permeability of the BBB might be greatly influenced by cerebral blood flow. 52

Human peripheral blood mononuclear cells (PBMCs) are isolated from peripheral blood and feature round nuclei. They mainly comprise lymphocytes, monocytes, and NK cells. 53 Most PBMCs are naïve without immune effects. Importantly, the largest fraction, T cells, will develop into diverse subsets of Th1, Th2, Th17, or regulatory T cells (Treg cells) after activation by different cytokines. 54, 55 Monocytes in PBMCs can also be activated by proinflammatory 

EAE is a reliable murine model that can well simulate the occurrence and development of MS. 65 In the 11 included studies, EAE induction was accomplished using three methods (Table 1) protein content of CNS myelin and was recently proven to correlate with the severity of disease in MS patients. 66 In addition to the autoimmune component, the oral administration of cuprizone can cause whole-brain demyelination and gliosis and was used to establish the murine model in one study. Compared with the two previous methods, cuprizone induction is easier to operate but time-consuming (5 vs. 2 weeks). More importantly, female mice are more resistant to cuprizone induction, and estradiol/progesterone can protect against cuprizone-induced demyelination. 67, 68 The LA dosage was 5-100 mg/kg per day, and the mode of administration F I G U R E 2 Lipoic acid protects the central nervous system by immunomodulation and antioxidation. In the periphery, LA prevents inflammatory cells from crossing the BBB by inhibiting the expression of LFA-1, ICAM-1, VLA-4, VCAM-1, and MMP-9 and protects brain endothelial cells. In the CNS, LA modulates autoimmunity by inhibiting the activity of T cells/microglia and decreasing the expression of TNFα and IFNγ, and LA reduces oxidative stress by neutralizing ROS and NO

Yadav et al 33 Note: "-" indicates decreased expression or event compared with non-LA group, "+" indicates increased expression or enhanced activity, and "=" indicates no statistical difference.

Abbreviations: ADMA, asymmetric dimethylarginine; cAMP, cyclic adenosine monophosphate; EDSS, Expanded Disability Status Scale; GPX, glutathione peroxidase; HC, healthy control; ICAM-1, intercellular cell adhesion molecule-1; IL-, interleukin-; INFγ, interferonγ; MAD, malondialdehyde; MMP-9, matrix metalloprotein-9; NA, not available; PK, pharmacokinetics; SOD, superoxide dismutase; T25FW, Timed 25-Foot Walk; TAC, total antioxidant capacity; TGFβ, transforming growth factorβ; TNFα, tumor necrosis factorα.

included intramuscular injection (n = 5), intraperitoneal injection (n = 3), subcutaneous injection (n = 1), oral administration (n = 1), and general injection (n = 1). Only three studies indicated that a racemic form of LA was used, and the remaining eight studies did not report the specific form. 

Nuclear factor erythroid-2 related factor 2 (Nrf2) is a redox-sensitive transcription factor existing in the cytoplasm, and it will translocate to the nucleus when oxidative stress occurs. 77 In the nucleus, it binds to antioxidant response elements and initiates the transcription of over 200 detoxification genes. 78 In the rat brain, LA promoted Nrf2 translocation and the superoxide dismutase (SOD) activity to defend against oxidative stress. 79 Besides, LA upregulated the expression of Nrf2 and its downstream hemeoxygenase-1 to alleviate neuronal cell apoptosis. 80 In EAE mice, LA increased the expression of GSH and SOD to enhance antioxidant system activity ( Figure 2 ). Meanwhile, LA decreased the levels of ROS and lipid peroxidation in EAE mice. 32 These findings suggested that the LA-Nrf2-antioxidative system pathway might be involved in neurological improvement in EAE mice.

Open label, RCT NA 1200mg oral lipoic acid can achieve therapeutic serum levels. 

Twelve studies based on clinical trials were included to describe the role of LA in patients with MS ( LA appears quite safe, with a compliance rate of 80% to 97% in MS patients. 44 The most common adverse events are gastrointestinal intolerance and rash. Notably, the oral administration of 600 mg of R-LA showed approximately half less gastrointestinal discomfort than 1200 mg of the racemic form, while the bioavailability was nearly equivalent. 98 Taking LA after meals and enteric coating can also improve tolerability. 99 Furthermore, one case of maculopapular rash with fever was reported after 2400 mg/day for 1 week, and the symptoms were resolved only by stopping intake. 100 The other three cases of rash were found in two double-blind RCTs, but they seemed to be milder and only affected the skin. 36, 101 Consistently, in patients with diabetic polyneuropathy or other CNS diseases, few AEs were found, and some studies did not set AEs as an endpoint. [102] [103] [104] Consistent with our results, a meta-analysis including 71 placebo-controlled clinical studies found that LA was associated with no increased risk of AEs, even with pregnancy status. 105 For future studies, seeking the balance of effective dose and fewer AEs will be necessary.

LA showed mixed antioxidative and anti-inflammatory effects ( Figure 2) . A 12 weeks double-blind RCT reported an apparent improvement in serum total antioxidant capacity in 52 RRMS subjects. 106 However, the specific approach remained confusing because no difference was found in the serum GSH:GSSG ratio, superoxide dismutase, and GSH peroxidase activity. 34, 107 Notably, LA reduced the content of asymmetric dimethylarginine (a major endogenous inhibitor of endothelial NO synthase) in the blood of MS patients. 108 In future, considering that LA can chelate heavy metals, including iron and copper, investigating whether LA can function to prevent gadolinium-related contrast magnetic resonance imaging (MRI) will be interesting. 109 Additionally, another key point is whether improved peripheral antioxidant capacity can exactly reflect the redox status in the CNS, a topic that warrants investigation. In summary, LA is one of the most promising antioxidants to alleviate oxidative stress in the CNS because of its high water and fat solubility.

Regarding immunomodulation, LA protects the BBB from disruption by peripheral inflammatory cells. On the one hand, MMP-9

released by T cells degrades components of the extracellular matrix, 110 and ROS produced during monocyte binding to ECs result in the loss of tight junctions. 9 On the contrary, when endothelial cells are activated by TNFα/IFN-γ, ICAM-1 is overexpressed and binds to LFA-1, initiating cytoskeletal rearrangement in brain ECs. 111, 112 These events that disrupt the BBB explain the finding that high levels of MMP-9/ICAM-1 are present before the appearance of new MRI-based gadolinium-enhancing lesions in MS patients. [113] [114] [115] In response, a two-week LA supplement decreased the levels of serum MMP-9 and ICAM-1 in 33 patients. 100 Another twelve weeks of LA supplementation decreased the levels of serum IFNγ and IL-4 in 46 RRMS patients, but the serum TNFα and IL-6 levels showed no difference. 35 Notably, a recent study found that the oral administration of meglumine cAMP promoted BBB integrity, suggesting that LA may maintain the normal functioning condition of ECs through a similar effect. 116 In summary, by stabilizing the BBB, LA can disturb inflammation progression in the CNS. Additionally, using LA orally appears to benefit MS patients and help to reduce relapse tendency. Future studies should note the clinical heterogeneity of a relatively short trial duration, LA forms, and different MS stages.

We comprehensively summarized the current findings of LA regarding pharmacokinetics, efficacy, safety, and mechanisms in To date, the achievements of LA supplementation are exciting, but the evidence is not sufficiently strong, being limited primarily by the short trial duration and insufficient study quantity. Thus, multicenter and long-term controlled studies are encouraged to determine the strength of LA orally, an appropriate dose for long-term usage, and the most suitable combination therapy. As our understanding of the role of LA improves, we hope to uncover the best treatment regimens for MS patients.

The authors sincerely thank Dexing Xun (the scientific illustrator from Nanchang University School of Pharmacy) for the artwork in Figure 2 .

The authors declare no financial or other conflicts of interest.

Hongsheng Xie contributed to investigation, data curation, and writing (original draft). Xiufang Yang contributed to investigation, data curation, and writing (editing). Yuan Cao involved in data curation. Xipeng Long contributed to validation and resources.

Huifang Shang involved in investigation. Zhiyun Jia contributed to conceptualization, supervision, writing (revising), and funding acquisition.

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Zhiyun Jia https://orcid.org/0000-0003-1886-5654

Multiple sclerosis

Multiple sclerosis: clinical aspects

The pressing questions in multiple sclerosis care in the era of COVID-19

Progress in multiple sclerosis research: an example of bedside to Bench

Secondary progressive multiple sclerosis: current knowledge and future challenges

Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis

Outside-in' demyelination in MS

Inflammatory cortical demyelination in early multiple sclerosis

Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier in vitro

Multiple Sclerosis: mechanisms and Immunotherapy

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Therapeutic decisions in multiple sclerosis: moving beyond efficacy

Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis

Progressive multiple sclerosis: from pathophysiology to therapeutic strategies

Nutraceuticals against neurodegeneration: a mechanistic insight

Radical changes in multiple sclerosis pathogenesis

Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis

Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis

Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis

Measurement of lowmolecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis

Peroxynitrite formation within the central nervous system in active multiple sclerosis

A review of various antioxidant compounds and their potential utility as complementary therapy in multiple sclerosis

Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebocontrolled trial

Insights on the use of α-lipoic acid for therapeutic purposes

Biochemical and clinical relevance of alpha lipoic acid: antioxidant and anti-inflammatory activity, molecular pathways and therapeutic potential

Antioxidant activity of dihydrolipoate against microsomal lipid peroxidation and its dependence on alpha-tocopherol

Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo

Antioxidant action of ubiquinol homologues with different isoprenoid chain length in biomembranes

Alpha-Lipoic acid as a biological antioxidant

Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers

α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: a review

Alpha-lipoic acid mitigates toxic-induced demyelination in the corpus callosum by lessening of oxidative stress and stimulation of polydendrocytes proliferation

Pharmacokinetic study of acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters

Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: a randomized clinical trial

Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: a double-blind, placebocontrolled, randomized clinical trial

Lipoic acid in secondary progressive MS: a randomized controlled pilot trial

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis

Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA

Interaction of α-lipoic acid with the human Na+/multivitamin transporter (hSMVT)*

Transepithelial transport of α-lipoic acid across human intestinal Caco-2 cell monolayers

Lipoic acid stimulates cAMP production in healthy control and secondary progressive MS subjects

Lipoic acid pharmacokinetics at baseline and 1 year in secondary progressive MS

Comparing the bioavailability of two forms of lipoic acid in multiple sclerosis

Modeling Psychomotor retardation using iPSCs from MCT8-deficient patients indicates a prominent role for the blood-brain barrier

Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/ SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells

Role of combined lipoic acid and vitamin D3 on astrocytes as a way to prevent brain ageing by induced oxidative stress and iron accumulation

Distribution of [7,8-14C] a-lipoic acid in selected organs of the rat after single oral and intravenous administration with special respect to nervous tissues

α-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats

Effect of DLα-lipoic acid on the status of lipid peroxidation and lipids in aged rats

Distribution study of orally administered lipoic acid in rat brain tissues

The Impact of Food Bioactives on Health: In vitro and ex vivo models

Regulatory T cells and immune tolerance

Follicular helper CD4 T cells (TFH)

α lipoic acid inhibits human T-cell migration: Implications for multiple sclerosis

Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling

Alpha-lipoic acid modulates NF-kappaB activity in human monocytic cells by direct interaction with DNA

Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis

Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells

Lipoic acid modulates inflammatory responses of monocytes and monocyte-derived macrophages from healthy and relapsing-remitting multiple sclerosis patients

Lipoic acid stimulates cAMP production in T lymphocytes and NK cells

Effects of lipoic acid on primary murine microglial cells

Lipoic acid prevents axonal spheroid formation and severing in adult neurons during oxidative stress

Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination

Correlation between anti-myelin proteolipid protein (PLP) antibodies and disease severity in multiple sclerosis patients with PLP response-permissive HLA types

17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice

Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication

Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis

α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis

Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity

α-Lipoic acid enhances endogenous peroxisome-proliferator-activated receptor-γ to ameliorate experimental autoimmune encephalomyelitis in mice

Neuroprotective effects of α-lipoic acid on long-term experimental autoimmune encephalomyelitis

Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model

Antiallodynic effects of alpha lipoic acid in an optimized RR-EAE mouse model of MSneuropathic pain are accompanied by attenuation of upregulated BDNF-TrkB-ERK signaling in the dorsal horn of the spinal cord

Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis

Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes

Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells

α-Lipoic acid alleviates pentetrazol-induced neurological deficits and behavioral dysfunction in rats with seizures via an Nrf2 pathway

Alpha lipoic acid inhibits oxidative stress-induced apoptosis by modulating of Nrf2 signalling pathway after traumatic brain injury

Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis

Lipoic acid reduces inflammation in a mouse focal cortical experimental autoimmune encephalomyelitis model

An organic CD4 inhibitor reduces the clinical and pathological symptoms of acute experimental allergic encephalomyelitis

The nuclear factor NF-kappaB pathway in inflammation

α-Lipoic acid inhibits matrix metalloproteinase-9 expression by inhibiting NF-κB transcriptional activity

Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription

KEAP1-Modifying Small Molecule Reveals Muted NRF2 Signaling Responses in Neural Stem Cells from Huntington's Disease Patients

Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists

Roles of peroxisome proliferator-activated receptor gamma on brain and peripheral inflammation

Protective effect of telmisartan against oxidative damage induced by high glucose in neuronal PC12 cell

Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity

Correlation between the clinical disability and T1 hypointense lesions' volume in cerebral magnetic resonance imaging of multiple sclerosis patients: a systematic review and metaanalysis

Relapsing-remitting multiple sclerosis: patterns of response to disease-modifying therapies and associated factors: a national survey

Clinical course and changes of soluble interleukin-2 receptor and soluble forms of intercellular adhesion molecule-1 (ICAM-1) in serum of multiple sclerosis patients

Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis

Lipoic acid and multiple sclerosis: a randomized controlled conical trial

Lipoic Acid for Progressive Multiple Sclerosis (MS)

Gastrointestinal tolerability and absorption of R-versus R, S-lipoic acid in progressive multiple sclerosis: a randomized crossover trial

Tolerability, adherence, and patient outcomes

Lipoic acid in multiple sclerosis: a pilot study

Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial

Effects of alpha-lipoic acid supplementation on plasma adiponectin levels and some metabolic risk factors in patients with schizophrenia

Effect of alphalipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy

Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems

Safety evaluation of alphalipoic acid supplementation: a systematic review and meta-analysis of randomized placebo-controlled clinical studies

Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: a randomized controlled clinical trial

Evaluation of serum glutathione changes as a mechanism of action of lipoic acid

Effect of lipoic acid on oxidative stress in multiple sclerosis patients: a double blind randomised clinical trial

Potential role of lipoic acid as a chelator in prevention and treatment of gadolinium brain retention

Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis

ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines

Intercellular adhesion molecule 1 activation induces tyrosine phosphorylation of the cytoskeleton-associated protein cortactin in brain microvessel endothelial cells

Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis

Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging

Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis

Reduced neuronal cAMP in the nucleus accumbens damages blood-brain barrier integrity and promotes stress vulnerability

Role of lipoic acid in multiple sclerosis